Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer

This study has been completed.
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
CMX Research
ClinicalTrials.gov Identifier:
NCT00426777
First received: January 24, 2007
Last updated: February 2, 2012
Last verified: February 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2009
  Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)